T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

Amplification of c-erbB2 has been reported in over 30% of uterine serous carcinoma (USC) and found to confer poor survival because of high proliferation and increased resistance to therapy. In this study, we evaluated for the first time Trastuzumab emtansine (T-DM1), a novel antibody–drug conjugate,...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: English, Diana P, Bellone, Stefania, Schwab, Carlton L, Bortolomai, Ileana, Bonazzoli, Elena, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Lopez, Salvatore, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Santin, Alessandro D
פורמט: Artigo
שפה:Inglês
יצא לאור: Blackwell Publishing Ltd 2014
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4302675/
https://ncbi.nlm.nih.gov/pubmed/24890382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.274
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים